FDA Has Approved A New Medication Treatment For Migraines In Adults

Updated Feb 6, 2025 | 05:09 PM IST

SummaryMany people use the terms ‘migraine’ and ‘headache’ interchangeably. This leads many people to believe that migraines are not as serious as people make them out to be, and that cannot be more wrong, migraines have a major effect on a person’s lifestyle and the new approved medication may prove to be a great relief!
(Credit-Canva)

(Credit-Canva)

Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

End of Article

Simple Androgen Blood Test Could Identify Endometriosis With 95% Accuracy

Updated Jul 15, 2026 | 06:00 PM IST

SummaryThe researchers discovered that women with endometriosis consistently had higher levels of 11-ketotestosterone, one of the 11-oxygenated androgens, which enabled them to differentiate women with and without endometriosis.
Simple Androgen Blood Test Could Identify Endometriosis With 95% Accuracy

Credit: iStock

A simple blood test that measures androgen hormone levels could help diagnose endometriosis with more than 95 per cent accuracy, according to new research.

The University of Edinburgh-led findings offer hope for a faster, less invasive way to detect the condition, which affects an estimated 10 per cent of women of reproductive age worldwide—around 190 million people—and often takes years to diagnose.

The researchers found that women with endometriosis have a distinct androgen hormone profile in their blood, suggesting the condition could one day be identified through a simple blood test rather than invasive procedures.

Study Identifies a Unique Hormone Signature

Also read: NHS To Roll Out Two 'Gamechanger' Tests for Faster Endometriosis Diagnosis: Know How They Work

The research team analyzed blood samples from 159 women with confirmed endometriosis and 57 women without the condition. Their investigation focused on androgen hormones, including a lesser-studied group known as 11-oxygenated androgens, which are produced by the adrenal glands.

The researchers discovered that women with endometriosis consistently had higher levels of 11-ketotestosterone, one of the 11-oxygenated androgens.

Using this distinct hormone profile, the team was able to differentiate women with and without endometriosis, correctly identifying more than 95 per cent of those with the condition.

If validated in larger clinical studies, the test could reduce reliance on invasive diagnostic procedures such as laparoscopy and help women receive treatment much earlier.

The findings also provide new insights into the role of androgens in the development of endometriosis and may help guide future treatment strategies.

Why Androgens Matter

Endometriosis occurs when tissue similar to the lining of the uterus grows outside the womb. These cells respond to hormones, leading to inflammation, chronic pelvic pain and the formation of scar tissue.

While the disease is known to be influenced by the female hormones estrogen and progesterone, the role of androgens—often referred to as male hormones, though they are naturally present in women as well—has received comparatively little attention.

The researchers believe the newly identified androgen signature could improve understanding of how the disease develops and progresses.

Read More: 13.5 Million Children Remain Zero-Dose In 2025 Despite Global Vaccination Gains: UN Report

Why Earlier Diagnosis Is Important

Diagnosing endometriosis remains a major challenge. Current methods include ultrasound, MRI scans and laparoscopy—a surgical procedure in which a camera is inserted through a small incision in the abdomen to confirm the presence of endometrial-like tissue.

Because symptoms often overlap with those of other conditions, many women wait years before receiving a diagnosis. Earlier diagnosis could help reduce prolonged pain, limit disease progression and allow patients to begin treatment sooner, said the researchers, while stressing the need for larger studies.

What Is Endometriosis?

According to the World Health Organization (WHO), endometriosis is a chronic condition in which tissue similar to the lining of the uterus grows outside the uterus. It most commonly affects the ovaries, fallopian tubes and the tissue lining the pelvis.

The condition can begin with a person's first menstrual period and continue until menopause. Common symptoms include severe pelvic pain, painful periods, pain during intercourse, bowel or urinary symptoms during menstruation, and difficulty conceiving.

End of Article

COVID Spikes In India: Experts Allay Fears, Stress Vaccination And Masks

Updated Jul 15, 2026 | 05:00 PM IST

SummaryThe experts said that the current wave is being driven by Omicron subvariants — the JN.1 variant and the BA.3.2 variant — that remain highly transmissible but are not causing severe illness in most people.
COVID Spikes In India: Experts Allay Fears, Stress Vaccination And Masks

Credit: iStock

The recent rise in COVID-19 cases and deaths in Andhra Pradesh has renewed concerns over the virus, prompting neighbouring states such as Tamil Nadu and Odisha to step up surveillance. Andhra Pradesh has reported three COVID-related deaths along with several active cases.

However, health experts say the current situation does not indicate a major public health threat and have urged people to focus on prevention rather than panic.

Tamil Nadu's Health Department has also clarified that there is no evidence of a highly virulent COVID-19 variant circulating in the state. Officials noted that current COVID-19 infections remain lower than in previous years.

Virus Continues To Evolve

Also read: Omicron Sub-Lineages Likely Behind COVID Surge In India: Why Deaths Are Occurring

"The SARS-CoV-2 virus never truly disappears; it continues to resurface through new mutations. Viral strains naturally mutate as part of their evolution, making viral illnesses highly dynamic," Dr Abha Mashur, Pulmonologist at Lilavati Hospital and Research Centre, Mumbai, told HealthandMe.

She said the key concern is not the emergence of new variants, but the severity of disease they cause.

"At present, we are predominantly seeing upper respiratory involvement and milder cases of viral illness," said Dr Mashur, adding that Lilavati Hospital has admitted only one or two COVID-19 patients recently, all of whom required monitoring but experienced only mild illness.

Who Is At Higher Risk?

While most infections are mild, experts caution that certain groups remain vulnerable to severe disease. These include:

  • Elderly individuals
  • Pregnant women
  • People with chronic heart disease
  • Patients with COPD or interstitial lung disease (ILD)
  • Those with chronic kidney or liver disease
  • Immunocompromised individuals.

Read More: 13.5 Million Children Remain Zero-Dose In 2025 Despite Global Vaccination Gains: UN Report

Omicron Subvariants Circulating In India

According to Dr Mashur, the current wave is being driven by Omicron subvariants — the JN.1 variant and the BA.3.2 variant — that remain highly transmissible but are not causing severe illness in most people.

JN.1: The expert explained that the JN.1 variant is highly transmissible and possesses enhanced immune-evasion capabilities, allowing it to partially bypass immunity from previous infection or vaccination. However, she said it continues to cause predominantly mild illness compared to earlier variants.

BA.3.2: The BA.3.2 variant has accumulated a large number of mutations, raising concerns about immune escape. Despite this, available evidence suggests it has not led to more severe disease and is not currently considered a cause for alarm.

No Need for Panic

The experts stressed that the current rise in cases should encourage vigilance rather than fear. Vaccination, masking in high-risk settings, and early medical consultation remain the most effective tools to reduce transmission and protect vulnerable populations.

"The current situation should not create panic, but should prompt people to seek medical attention early. Those who develop symptoms of a viral infection should avoid public spaces and consult a doctor promptly so that transmission can be curtailed at the earliest," Dr Mashur said.

Dr Neha Rastogi, Senior Consultant, Infectious Diseases, Fortis Memorial Research Institute, Gurugram, urged people to continue following basic preventive measures.

"To reduce the risk of infection, people should stay up to date with COVID-19 vaccinations, wear masks in crowded indoor settings, maintain hand hygiene, ensure good ventilation, and avoid close contact when unwell. Anyone experiencing symptoms such as fever, cough, or breathlessness should get tested and seek timely medical advice."

End of Article

Eating Late At Night May Be Linked to Higher Body Fat Even Without Extra Calories: Recent Study

Updated Jul 15, 2026 | 04:00 PM IST

SummaryYour meal timings matter more than you think. A recent study confirms that night owls tend to have a poor metabolic health compared to early risers.
Eating Late At Night May Be Linked to Higher Body Fat Even Without Extra Calories: Recent Study

Credit: AI

The debate around the effects of late-night eating on metabolism and overall fitness is not new. A new study has found a strong link between night owls’ time of eating and their metabolic health.

The study observes that those who stayed late at night tend to have poor metabolic health and effectively more body fat than those who didn’t, as they tend to have the lion’s share of their calories in the later part of the day.

How Was The Study Conducted?

The study examines an important area of nutrition called chrononutrition, which basically refers to how the time of eating affects the body’s circadian rhythm. It investigated how chronotype is associated with dietary intake, meal timing, body composition, and metabolic health.

Published in Frontiers in Nutrition, the study observed 287 healthy women aged 18 to 45 from New Zealand. Their food intake was studied for five days along with their meal timings.

Participants were classified as morning, intermediate, or evening chronotypes using a validated questionnaire. They also recorded everything they ate and drank over five days.

Researchers studied body composition using dual-energy X-ray absorptiometry (DXA), a highly accurate method for measuring body fat, and analyzed metabolic markers including glucose, insulin, cholesterol, and triglycerides.

Also read: India Gets Its First Plant-Based Vitamin D3: What You Need to Know

What Did The Study Find?

The study found that women with an evening chronotype had higher body mass index (BMI), a higher percentage of body fat, and more abdominal fat compared with morning and intermediate chronotypes.

Interestingly, these differences were observed even though total daily calorie intake did not significantly differ between the groups.

The study also found that rather than eating more food overall, evening chronotypes tended to delay their meals and consumed a larger proportion of their daily calories later in the day.

The findings indicate that when people eat may play an important role in metabolic health along with what and how much they eat.

The researchers wrote, “Our findings indicate that women with a later chronotype tend to have higher body fat and consume a greater proportion of their energy intake later in the day.”

Also read: Why Sustainable Weight Loss Requires More Than Cutting Calories

Why Meal Timings Affect Your Metabolism?

Although the current study directly does not determine whether late eating directly causes higher body fat, it observes a pattern that chronotype and meal timing are important factors to consider in order to achieve a better fitness level.

The body's internal clock is responsible for regulating many metabolic processes, including blood sugar control, insulin sensitivity, and digestion, among others. Late night eating not only interferes with insulin sensitivity but also impairs your metabolic health.

Research has repeatedly shown that these processes function a lot more efficiently earlier in the day. Eating a large proportion of daily calories late in the evening is therefore less favorable for metabolism as it can lead to increased fat accumulation over time.

With time, those with evening chronotype are at a greater risk of obesity and obesity-related chronic lifestyle disorders like hypertension, diabetes, high cholesterol, heart disease, and more.

End of Article